A Multicenter, Interventional, Open-label and Single-arm Study to Investigate the Effect of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D
Latest Information Update: 24 Oct 2024
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure; Ventricular arrhythmias
- Focus Therapeutic Use
- Acronyms RHYTHM
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 17 Oct 2024 The protocol has been amended to include modification and addition of study primary endpoints.
- 20 Feb 2024 Status changed from completed to discontinued.
- 22 Nov 2023 Status changed from discontinued to completed.